1. Home
  2. CRON vs AMBQ Comparison

CRON vs AMBQ Comparison

Compare CRON & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRON
  • AMBQ
  • Stock Information
  • Founded
  • CRON N/A
  • AMBQ 2010
  • Country
  • CRON Canada
  • AMBQ United States
  • Employees
  • CRON N/A
  • AMBQ N/A
  • Industry
  • CRON Medicinal Chemicals and Botanical Products
  • AMBQ Semiconductors
  • Sector
  • CRON Health Care
  • AMBQ Technology
  • Exchange
  • CRON Nasdaq
  • AMBQ Nasdaq
  • Market Cap
  • CRON 809.4M
  • AMBQ 673.1M
  • IPO Year
  • CRON N/A
  • AMBQ 2025
  • Fundamental
  • Price
  • CRON $2.50
  • AMBQ $34.34
  • Analyst Decision
  • CRON
  • AMBQ Buy
  • Analyst Count
  • CRON 0
  • AMBQ 4
  • Target Price
  • CRON N/A
  • AMBQ $43.75
  • AVG Volume (30 Days)
  • CRON 4.2M
  • AMBQ 237.0K
  • Earning Date
  • CRON 08-07-2025
  • AMBQ 09-04-2025
  • Dividend Yield
  • CRON N/A
  • AMBQ N/A
  • EPS Growth
  • CRON N/A
  • AMBQ N/A
  • EPS
  • CRON 0.05
  • AMBQ N/A
  • Revenue
  • CRON $130,282,000.00
  • AMBQ $76,589,000.00
  • Revenue This Year
  • CRON $19.67
  • AMBQ N/A
  • Revenue Next Year
  • CRON $30.56
  • AMBQ N/A
  • P/E Ratio
  • CRON $52.23
  • AMBQ N/A
  • Revenue Growth
  • CRON 28.01
  • AMBQ 50.25
  • 52 Week Low
  • CRON $1.60
  • AMBQ $32.89
  • 52 Week High
  • CRON $2.77
  • AMBQ $51.76
  • Technical
  • Relative Strength Index (RSI)
  • CRON 55.55
  • AMBQ N/A
  • Support Level
  • CRON $2.47
  • AMBQ N/A
  • Resistance Level
  • CRON $2.71
  • AMBQ N/A
  • Average True Range (ATR)
  • CRON 0.11
  • AMBQ 0.00
  • MACD
  • CRON -0.02
  • AMBQ 0.00
  • Stochastic Oscillator
  • CRON 36.70
  • AMBQ 0.00

About CRON Cronos Group Inc. Common Share

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Share on Social Networks: